Physician profile
Christopher J Cherry
NPI 1609861293
$3,636.07
in general payments reported to CMS, 2019-2025
21 companies · $938 in 2025
The $938 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,359 · 2020: $52.43 · 2021: $132 · 2022: $341 · 2023: $252 · 2024: $562 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,316.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $445.33 | 2019-2025 | |
| Pfizer INC. | $310.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $298.94 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $290.30 | 2019-2025 | Lifevest |
| Abbott Laboratories | $286.01 | 2022 | |
| Medtronic, INC. | $234.18 | 2021-2024 | Micra, Cobalt Dr Mri Surescan |
| Alnylam Pharmaceuticals INC. | $110.64 | 2024-2025 | Amvuttra |
| Abiomed | $98.44 | 2021 | |
| Novo Nordisk INC | $82.94 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.06 | 2025 | Jardiance |
| Amgen INC. | $26.42 | 2019 | |
| Boston Scientific Corporation | $18.21 | 2024 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $15.09 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.93 | 2025 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $14.56 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $13.26 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.